Bionure Inc.’s MS Drug Candidate Shows Positive Results for Myelin Repair in Cell Culture Assay.
PRESS RELEASE. MAY 27, 2014.
Bionure Inc. today announced its drug candidate, BN201, was shown to promote myelination — the cellular process of repairing the protective sheath surrounding nerves that is damaged in people with multiple sclerosis (MS). The pre-clinical study was conducted in a novel cell-culture assay developed by the Myelin Repair Foundation (MRF) and assessed at the Foundation’s Translational Medicine Center under a previously announced collaborative agreement.